Amgen said a drug combination reduced the risk of death for patients with an aggressive form of lung cancer
Amgen said interim Phase 3 DeLLphi-305 results showed its Imdelltra (tarlatamab) plus AstraZeneca’s Imfinzi (durvalumab), used as first-line maintenance therapy for extensive-stage small cell lung cancer, reduced the risk of death by 58% versus Imfinzi alone. Median overall survival was 21.1 months with the combination, compared with 12.7 months.
More context
An interim Phase 3 trial found that combining Amgen’s Imdelltra (tarlatamab) with AstraZeneca’s Imfinzi (durvalumab) reduced the risk of death by 58% in people with extensive-stage small cell lung cancer receiving first-line maintenance treatment, compared with Imfinzi alone. The DeLLphi-305 results were presented Oct. 24 at the European Society for Medical Oncology congress in Madrid and published in the New England Journal of Medicine, BigGo Finance reported.
Median overall survival was 21.1 months with the combination and 12.7 months with Imfinzi alone. Nearly 80% of combination-treated patients were alive at one year, versus 53%; median progression-free survival was 7.4 months versus 1.9 months. Grade 3 or higher adverse events occurred in 20.9% of the combination group, roughly twice the rate with Imfinzi alone. Dana-Farber said cytokine release syndrome occurred in 49.6% of patients, most often at grade 1 or 2.
Was this story useful?
What was the main problem? (optional)
Reporting
- Bloomberg — Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer - Bloomberg
- prnewswire.com — IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- mezha.net — Amgen-Imfinzi combination cuts death risk 58% in small cell lung cancer trial | Межа
- biggo.com — Amgen, AstraZeneca Combo Cuts Death Risk 58% in Small Cell Lung Cancer, Extends Survival by 8.4 Months — BigGo Finance
- dana-farber.org — Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026 | Dana-Farber Cancer Institute
Verifier’s note
The results report the same DeLLphi-305 trial finding: Amgen’s Imdelltra plus AstraZeneca’s Imfinzi improved survival for patients with extensive-stage small cell lung cancer, with the company reporting a 58% reduction in risk of death. The reports are dated October 24–25, 2026, consistent with the proposed event’s timing.